SLS ▾TradingViewOVTLYR consoleNews (1w)Earnings search — SELLAS Life Sciences Group, Inc.

Healthcare · ETF XLV · as of 2026-09-18

Daily · EMA 10 / 20 / 50 · SMA 200 · VolPress: buy/sell split, 20-SMA, white dot = above avg · · E = earnings · RS vs SPY ⓘ · ● RS new high ⓘ
SLS
SELLAS Life Sciences Group, Inc. NCM
Healthcare · Biotechnology

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Market cap
2.3B
P/E (TTM)
-
EPS (TTM)
-0.25
Employees
13
IPO
2008-03-12
Website
sellaslifesciences.com

Price & today

$11.49 ATR(14) 1.05 (9.13%)
Stock today-0.35%
Sector ETF today-0.25%
Residual (stock-specific)-0.10%

Sector correlation

20-day correlation with XLV0.15
60-day correlation with XLV0.18
Status normal

Decoupling fires when 60d corr − 20d corr > 0.20: stock used to track its sector but the relationship has weakened recently.

Technicals

10 EMA$12.20
20 EMA$12.60
50 EMA$12.20
EMA stackNEUTRAL
RSI(14)41.6
52-week high distance+87.13%
52-week low distance+744.85%

Signals

Market F&G46.9
Bull%12.2%
OVTLYR status SELL (3d)
Sector rank#217
Next earnings 2026-11-10 (TNS, 52d)
TradingView OVTLYR console More news (Google) Sector dashboard (XLV)

MarketSmith metrics - our compute

RS Rating
10.9
ADR%
8.7
RMV (tight)
0.0
Ext (ATR>20EMA)
-1.1
Rel Vol
208.0%
U/D 50d
0.94
U/D 25d
0.91
Accum/Dist 25d
4 / 4
EPS YoY
+29.0%
LoD dist
41.0
Off 52w High
27.6%
Above 52w Low
726.6%
1W / 1M
-0.5 / -17.0
Avg $Vol 50d
88.4M
Mkt Cap (B)
2.3
Trend 8/8
no
Leads Group
no
Sector XLV
+1.8% 1W
Base len (VCP)
10wk (9/9)
Coil (base shape)
85TVPX
not available: revenue(no EDGAR qtrs=1 fact)
What do these abbreviations mean?
RS Rating
- IBD-style relative strength vs SPY (weighted 3/6/9/12-mo). 70+ = leaders pool, 80+ = strong.
ADR%
- average daily range over 20 days. 4%+ = the fast movers the playbook prefers (selection order, not a gate).
RMV (tight)
- Relative Measured Volatility, 15 bars, scaled 0-100. <15 = tight coiled base (green), <35 moderate, high = loose/expanding - not a base right now.
Ext (ATR>20EMA)
- how many ATRs price sits above its 20-EMA. ≤1 = in value (green), >2 = extended/chasing (red) - prefer a pullback.
Rel Vol
- latest volume vs the 50-day average. 100% = normal; 140%+ = breakout confirmation.
U/D 50d / 25d
- up-day vs down-day volume over the window. 1.1+ = net accumulation (institutions buying); under 0.9 on the 25d = net selling.
Accum/Dist 25d
- heavy-volume up days vs heavy-volume down days in the last 25 sessions (close moved 0.2%+ on above-average volume). The institutional-participation footprint; 5+ distribution days = O'Neil caution line.
LoD dist
- close distance above the day low in % of ATR (100 = one full ATR off the low). High = strong close.
Off/Above 52w
- trend-template legs: within 25% of the 52-week high, at least 25% above the 52-week low.
Trend 8/8
- all 8 Minervini Trend Template criteria pass. Discovery floor, NOT an entry signal - entries come from the VCP pivot.
Base len (VCP)
- weeks since the VCP base started on the latest scan. 10wk+ bases carry the edge; short stacked bases test below random.

Fundamentals & valuation - reference, not entry inputs

P/E (TTM)
-
Fwd P/E
-
PEG
-
Price/Book
10.8
Profit margin
0.0%
ROE
-66.9%
Debt/Equity
1.4
Rev growth
-
Analyst target
$10 (-13%)
Analyst rating
STRONG_BUY
Institutional %
19.9%
Insider %
0.4%
Float %
90.9%
Valuation and analyst figures are Yahoo company stats (weekly refresh, ~3,000 larger names - blanks are honest gaps); logo, employees, website and IPO date are Massive company reference. Momentum/VCP entries do not use valuation - this card is context so you do not have to leave the page.

Company data - context read, not entry inputs

Industry rank
57 / 147
Industry
Biotechnology
Float
178.8M
Float turnover 20d
4.5%
Avg $Vol 20d / 50d
106.2M / 88.4M
Days to cover
8.3
Short % float
30.8%
Institutional %
19.9%
Weinstein stage
2
Float, short interest and institutional % come from Yahoo company stats, refreshed weekly for ~3,000 larger names - a blank means Yahoo does not publish the figure for this stock, not that it is zero. Dollar volume and float turnover are computed from our own price bars; industry rank from our rotation data; stage from the weekly chart.

Quarterly EPS - earnings acceleration

A dash in %Chg is deliberate: the year-ago figure was a loss, so a growth % would be meaningless. A dash in Sales means we have no revenue figure for that quarter - read it as a gap in our data, not as zero revenue.

QuarterEPS ($)%Chg YoYSales ($M)%Chg
Aug-24 -0.13 - - -
Nov-24 -0.10 - - -
Mar-25 -0.08 - - -
May-25 -0.07 - - -
Aug-25 -0.07 - - -
Nov-25 -0.06 - - -
Mar-26 -0.05 - - -
Aug-26 -0.05 - - -
† = SEC carries this same fiscal quarter under a second period-end with a materially different figure (hover for it) - a restatement, merger recast or successor-period split; %Chg is blanked when the two are more than 15% apart. It fires only when the two period-ends DISAGREE, so it is a floor, not a guarantee that the rest of the column shares one basis · ‡ = the revenue concept changed from the previous quarter WITH A FIGURE (hover for both) - a blank row in between is skipped, as the eye does - a step at that row is a change of basis, not necessarily of business · EPS = Yahoo eps_actual (the figure MarketSmith/Deepvue show) - whether a given quarter is GAAP or excludes a one-off follows the filing, so it can sit either side of another vendor's number; AAPL's Oct-24 row, the Sep-2024 fiscal quarter, is $0.97 here - GAAP, including the EU tax charge - where TradingView's year implies $1.64 · Sales ($M) = SEC EDGAR quarterly revenue (fiscal Q4 derived as FY minus 9-mo) · quarter = report month · %Chg blank = prior-year base under $0.05 (not meaningful).

Recent news - our DB (Finnhub + OVTLYR)